Press releases

With an ongoing program including toxicology- and safety studies, as well as GMP manufacturing of the drug candidate SOL-116, Lipum is in a late pre-clinical...
The Scientific Advisory Board of Lipum constitute an invaluable resource of experience from academic research to clinical practice within the field chronic...
Lipum will participate at the Naventus Life Science Summit, 29 September at Grand Hôtel in Stockholm. The event is organized by Naventus Corporate...
The drug candidate SOL-116 is an antibody and is thus a biological drug. In collaboration with Lipum's partner Abzena in San Diego, the development of...
The non-clinical program for toxicology- and safety studies of Lipum’s candidate drug (SOL-116) is carried out in collaboration with the contract...
CEO Einar Pontén comments: “Lipum has reached a stage when we are preparing for clinical trials. Important intermediate goals have been achieved...
Lipums CEO Einar Pontén will present Lipum at LSX Nordic Virtual Congress 6-17 September. The LSX Nordic Congress is annual investment and partnering...
For almost 50 years Professor of Pediatrics Olle Hernell and his group at Umeå University have been studying breast milk and its importance for nutrition...
What made you decide to start a company? “Research was being done at The University of Gothenburg into BSSL in collaboration with a local pharmaceutical...
The extra general meeting appointed Åsa Hansdotter and Ingemar Kihlström as new board members and decided that the board for the period until...

Investor relations